Duchenne Muscular Dystrophy Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Santhera Pharmaceuticals, Sarepta Therapeutics, Italfarmaco, Wave Life Sciences Ltd, Fib

Duchenne Muscular Dystrophy Pipeline constitutes 75+ key companies continuously working towards developing 75+ Duchenne Muscular Dystrophy treatment therapies, analyzes DelveInsight.

Duchenne Muscular Dystrophy Overview:

Duchenne muscular dystrophy (DMD) is one of the most severe inherited forms of muscular dystrophy and is the most common hereditary neuromuscular disorder, affecting individuals regardless of race or ethnicity. It is caused by mutations in the dystrophin gene, leading to the progressive degeneration and weakness of muscle fibers. The condition often begins with difficulty walking but worsens over time, eventually rendering individuals unable to perform daily activities and requiring wheelchair assistance. Cardiac and orthopedic complications are frequent, and death typically occurs in the twenties due to respiratory muscle weakness or cardiomyopathy. Current treatments focus on glucocorticoids and physiotherapy to help prevent orthopedic issues.

Dystrophin is a large cytoskeletal protein that facilitates interactions between the cytoskeleton, cell membrane, and extracellular matrix, and it is found at the plasma membrane in both muscle and non-muscle tissues. It is an essential component of the dystrophin-glycoprotein complex (DGC), which serves as a structural element in muscles. In DMD, the absence of both dystrophin and DGC proteins results in increased membrane fragility and permeability, calcium homeostasis disruption, and oxidative damage-all of which contribute to muscle cell necrosis. As DMD patients age, their muscles lose the ability to regenerate, with connective and adipose tissue gradually replacing muscle fibers.

Request for a detailed insights report on Duchenne Muscular Dystrophy pipeline insights @ https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Duchenne Muscular Dystrophy Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Duchenne Muscular Dystrophy Therapeutics Market.

Key Takeaways from the Duchenne Muscular Dystrophy Pipeline Report

DelveInsight's Duchenne Muscular Dystrophy pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Duchenne Muscular Dystrophy treatment.
In June 2024, REGENXBIO Inc. began enrolling a new group of boys aged 1 to 3 years in the Phase I/II AFFINITY DUCHENNE® trial, designed to assess the safety and effectiveness of RGX-202 for treating Duchenne muscular dystrophy.
Key Duchenne Muscular Dystrophy companies such as Santhera Pharmaceuticals, Sarepta Therapeutics, Italfarmaco, Wave Life Sciences Ltd, FibroGen, EDG 5506 Edgewise Therapeutics, Fordadistrogene movaparvovec, Daiichi Sankyo, Sarepta Therapeutics, Inc., ENCell, Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, Hansa Biopharma, and others are evaluating new drugs for Duchenne Muscular Dystrophy to improve the treatment landscape.
Promising Duchenne Muscular Dystrophy pipeline therapies in various stages of development include Vamorolone, Givinostat, Pamrevlumab, and others.

Duchenne Muscular Dystrophy Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Duchenne Muscular Dystrophy Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Duchenne Muscular Dystrophy treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Duchenne Muscular Dystrophy market.

Download our free sample page report on Duchenne Muscular Dystrophy pipeline insights @ https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Duchenne Muscular Dystrophy Emerging Drugs

Vamorolone: Santhera
Givinostat: Italfarmaco
Pamrevlumab: Fibrogen

Duchenne Muscular Dystrophy Companies

Over 75 key companies are working on developing therapies for Duchenne Muscular Dystrophy. Among these, Roche is one of the companies with drug candidates for Duchenne Muscular Dystrophy in the most advanced stage, namely Phase III.

DelveInsight's report covers around 75+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Duchenne Muscular Dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Duchenne Muscular Dystrophy Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Duchenne Muscular Dystrophy Therapies and Key Companies: Duchenne Muscular Dystrophy Clinical Trials and advancements @ https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Duchenne Muscular Dystrophy Pipeline Therapeutic Assessment
• Duchenne Muscular Dystrophy Assessment by Product Type
• Duchenne Muscular Dystrophy By Stage
• Duchenne Muscular Dystrophy Assessment by Route of Administration
• Duchenne Muscular Dystrophy Assessment by Molecule Type

Download Duchenne Muscular Dystrophy Sample report to know in detail about the Duchenne Muscular Dystrophy treatment market @ Duchenne Muscular Dystrophy Therapeutic Assessment @ https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Duchenne Muscular Dystrophy Current Treatment Patterns
4. Duchenne Muscular Dystrophy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Duchenne Muscular Dystrophy Late-Stage Products (Phase-III)
7. Duchenne Muscular Dystrophy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Duchenne Muscular Dystrophy Discontinued Products
13. Duchenne Muscular Dystrophy Product Profiles
14. Duchenne Muscular Dystrophy Key Companies
15. Duchenne Muscular Dystrophy Key Products
16. Dormant and Discontinued Products
17. Duchenne Muscular Dystrophy Unmet Needs
18. Duchenne Muscular Dystrophy Future Perspectives
19. Duchenne Muscular Dystrophy Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Duchenne Muscular Dystrophy Pipeline Reports Offerings: https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.